Hepatitis C
Drug research and approvals for hepatitis C: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 20, 2026, 50 studies of hepatitis C are recruiting on ClinicalTrials.gov, Health Canada has authorized 75 drug trials for it since 2013, FDA has 11 approved and 2 open orphan designations naming it, and the EU has 7 authorised medicines for it.
- Recruiting worldwide: 50
- Trials authorized in Canada: 75
- FDA orphan approvals: 11
- EU medicines: 7
- Hepatitis C Pharmacist, Physician, Patient Navigator Collaborative Care Model in Permanent Supportive HousingNCT07667101 · Not applicable · University of Washington · starts Jun 1, 2026
- Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to…NCT07487623 · Not applicable · University of Guadalajara · starts Oct 11, 2025
- California MEPS HubNCT07433985 · Not applicable · University of California, Los Angeles · starts Dec 1, 2025
- Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World DataNCT07419347 · Not reported · AbbVie · starts Feb 27, 2026
- Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine ClinicNCT07317687 · Not reported · West Virginia University · starts Jan 21, 2026
- Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)NCT07170748 · Not reported · MagIA Diagnostics · starts Jul 29, 2025
- Enhancing Uptake of Needle and Syringe Programs in Canadian Federal PrisonsNCT07122219 · Not applicable · McGill University Health Centre/Research Institute of the McGill University Health Centre · starts Oct 1, 2024
- Scaling Up Point-of-Care Hepatitis C Testing and Treatment in CanadaNCT07095192 · Not reported · McGill University · starts May 20, 2025
- Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C…NCT07040319 · Phase 1 / Phase 2 · National Institute of Allergy and Infectious Diseases (NIAID) · starts Jun 25, 2026
Approved 6
- SofosbuvirRNA-directed RNA polymerase inhibitor
- RitonavirHuman immunodeficiency virus type 1 protease inhibitor
- ParitaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- OmbitasvirNonstructural protein 5A inhibitor
- DasabuvirRNA-directed RNA polymerase inhibitor
- LedipasvirNonstructural protein 5A inhibitor
Phase 3 12 of 32
- RibavirinInosine-5'-monophosphate dehydrogenase 1 inhibitor
- Peginterferon alfa-2aInterferon alpha/beta receptor agonist
- DaclatasvirNonstructural protein 5A inhibitor
- SimeprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- TelaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- Peginterferon alfa-2bInterferon alpha/beta receptor agonist
- GrazoprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- AsunaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- ElbasvirNonstructural protein 5A inhibitor
- PibrentasvirNonstructural protein 5A inhibitor
- GlecaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- BeclabuvirRNA-directed RNA polymerase negative allosteric modulator
Phase 2 12 of 44
- ABT-072RNA-directed RNA polymerase inhibitor
- FilibuvirRNA-directed RNA polymerase inhibitor
- VelpatasvirNonstructural protein 5A inhibitor
- MiravirsenmicroRNA 122 antisense inhibitor
- VaniprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- RuzasvirNonstructural protein 5A inhibitor
- RavidasvirNonstructural protein 5A inhibitor
- BMS-986094RNA-directed RNA polymerase inhibitor
- CyclosporineCyclophilin A modulator
- TacrolimusFK506-binding protein 1A inhibitor
- RosuvastatinHMG-CoA reductase inhibitor
- CTS-1027Matrix metalloproteinase 3 inhibitor
Phase 1 or earlier 12 of 49
- EscitalopramSerotonin transporter inhibitor
- MethadoneMu opioid receptor agonist
- MoxifloxacinTopoisomerase IV inhibitor
- ITX-5061 free baseMAP kinase p38 alpha inhibitor
- BavituximabPhosphatidylserine inhibitor
- VoxilaprevirHepatitis C virus serine protease, NS3/NS4A inhibitor
- Interleukin-7
- BuprenorphineMu opioid receptor agonist
- KetoconazoleCytochrome P450 51 inhibitor
- Tenofovir disoproxilHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- EfavirenzHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- Ethinyl estradiolEstrogen receptor alpha agonist
How its trials ended
2,345 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 787 whose ending is known, 61% met their primary endpoint, 4% missed it and 35% stopped early.
- Completed, result not reported1,16350%
- Met its primary endpoint47720%
- Status unknown28012%
- Stopped: other or unclear1637%
- Ongoing1155%
- Stopped: enrollment or feasibility673%
- Missed its primary endpoint341%
- Stopped: sponsor or business decision181%
- Stopped: lack of efficacy131%
- Stopped: funding10<1%
- Stopped: safety5<1%
| May 26, 2025 | Phase 3, randomized, controlled, open-label study to compare the efficacy and safety of bemnifosbuvir-ruzasvir fixed-dose combination (bem/rzr fdc) versus…Bemnifosbuvir (AT-527)-ruzasvir (AT-038) | Atea Pharmaceuticals Inc | Closed |
| May 10, 2023 | A phase 2 open-label study to assess the safety and efficacy of bemnifosbuvir (BEM) and ruzasvir (RZR) in subjects with chronic hepatitis C virus (HCV)…Bemnifosbuvir (AT-527)/ Ruzasvir (AT-038) | Atea Pharmaceuticals Inc | Closed |
| Sep 9, 2022 | Safety, tolerability, and outcomes of velpatasvir/sofosbuvir in treatment of chronic hepatitis C virus during pregnancy (STORC):a single-arm, single-center,…Sofosbuvir-velpatasvir | University Health Network | Ongoing |
| Mar 30, 2022 | Randomised, open-label and parallel group trial to investigate the effects of oral bi 685509 alone or in combination with empagliflozin on portal hypertension…Bi 685509 / Empagliflozin | Boehringer Ingelheim (Canada) Ltd Ltee | Pending |
| Jul 15, 2021 | A multicenter, single-arm prospective study to evaluate safety and efficacy of gle/pib 8-week treatment in adults and adolescents with acute hepatitis C virus…Glecaprevir (ABT-493)-pibrentasvir (ABT-530) | AbbVie | Closed |
| Jul 20, 2017 | A phase 3 clinical study to evaluate the efficacy and safety of the combination regimen of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) in participants with…MK-3682B [grazoprevir (MK-5172)-ruzasvir (MK-8408)-uprifosbuvir (MK-3682)] | Merck & Co. (MSD) | Pending |
| Jul 20, 2017 | A phase II, randomized, open-label clinical trial to study the efficacy and safety of the combination regiment of MK-3682B (MK-5172 + MK-3682 + MK-8408 fixed…Grazoprevir (MK-5172)-ruzasvir(MK-8408)-uprifosbuvir (MK-3682) | Merck & Co. (MSD) | Ongoing |
| Jul 17, 2017 | A single arm, open label, multicenter study to evaluate the efficacy and safety of glecaprevir(GLE)/pibrentasvir(PIB) in treatment naïve adults with chronic…Glecaprevir (ABT-493)-pibrentasvir (ABT-530) | AbbVie | Closed |
| May 9, 2017 | A single arm, open-label study to evaluate the efficacy and safety of glecaprevir (GLE)/pibrentasvir (PIB) in treatment naïve adults with chronic hepatitis C…Glecaprevir (ABT-493)-pibrentasvir (ABT-530) | AbbVie | Closed |
| Apr 11, 2017 | A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (REACT)Sofosbuvir-velpatasvir | University of New South Wales | Closed |
| Jun 10, 2021 | EpclusaTreatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6… | Gilead Sciences, Inc. | Approved |
| Jun 10, 2021 | MavyretTreatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection… | AbbVie, Inc. | Approved |
| Mar 19, 2020 | EpclusaEPCLUSA is indicated for the treatment of adults and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic… | Gilead Sciences, Inc. | Approved |
| Aug 28, 2019 | SovaldiSOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without… | Gilead Sciences, Inc. | Approved |
| Aug 28, 2019 | SovaldiSOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without… | Gilead Sciences, Inc. | Approved |
| Aug 28, 2019 | HarvoniHARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV)… | Gilead Sciences, Inc. | Approved |
| Aug 28, 2019 | HarvoniHARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV)… | Gilead Sciences, Inc. | Approved |
| Apr 30, 2019 | MavyretMAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis… | AbbVie, Inc. | Approved |
| Apr 7, 2017 | SovaldiTreatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without… | Gilead Sciences, Inc. | Approved |
| Apr 7, 2017 | HarvoniTreatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6… | Gilead Sciences, Inc. | Approved |
| Jul 29, 2003 | RebetolTreatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older. | Schering Corporation | Approved |
| Jul 16, 2015 | ombitasvir/paritaprevir/ritonavir and dasabuvirTreatment of pediatric patients with hepatitis C virus infection (0 through 16 years of age) | Abbvie, Inc. | Designated |
| Feb 17, 2012 | Silibinin-C-2',3-dihydrogensuccinate, disodium saltPrevention of recurrent hepatitis C in liver transplant patients | Viatris Specialty LLC | Designated |
| Jul 26, 2017 | MaviretGlecaprevir; pibrentasvir | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
| Jul 26, 2017 | VoseviSofosbuvir; velpatasvir; voxilaprevi | Gilead Sciences Ireland UC | EMA ↗ |
| Jul 22, 2016 | ZepatierElbasvir; grazoprevir | Merck Sharp & Dohme B.V. | EMA ↗ |
| Jul 6, 2016 | EpclusaSofosbuvir; velpatasvir | Gilead Sciences Ireland UC | EMA ↗ |
| Nov 17, 2014 | HarvoniLedispavir; sofosbuvir | Gilead Sciences Ireland UC | EMA ↗ |
| Jan 16, 2014 | SovaldiSofosbuvir | Gilead Sciences Ireland UC | EMA ↗ |
| Jun 20, 2002 | PegasysPeginterferon alfa-2a | pharmaand GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA